Clinical studies

In oncology, the use of cfDNA as a biomarker allows to differentiate cancer patients from healthy people and to follow the efficiency of a drug therapy. With leading academic and health organisations, our clinical research programmes aim to develop cfDNA size and concentration profiling for treatment results prediction and cancer detection tests.

Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer
SChISM: Size cfDNA Immunotherapies Signature Monitoring

Purpose of the study:
The goal of the study is to evaluate the use of cfDNA to predict patients’ potential positive ou negative response to a given immunotherapy treatment and to study longitudinal therapy response monitoring.

Partners:
Partners: APHM, ID Solutions Oncology, INRIA-COMPO

More information
CfDNA size and concentration profile of healthy donors
DIAL: DNA size baseline

Purpose of the study:
Using the BIABOOSTER platform, the DIAL study, aims to establish a typical cfDNA profile (concentration and/or size distribution) in healthy subjects, regardless of age, sex, morphology, or mass index. Then, in subsequent studies, this “reference profile” could be compared to those observed in the case of various pathologies.

Partners:
EFS-Lille, EFS Marseille, ID Solutions Oncology

More information
Cell free DNA quantification and qualification to predict early rejection after lung transplantation
LARA

Purpose of the study:
The objective of this study is to identify and validate new biomarkers carried by cfDNA, to predict potential acute cellular rejection in patients who have undergone lung transplantation.

Partners:
EFS – Marseille – France

More information
Main office:

478 rue de la Découverte
31670 LABEGE – France
Tel. +33 (0)5 31 61 50 90

  • Analytical platforms

FOLLOW US

Copyright © 2024 Adelis SAS